Bochuang Bio Completes Angel Funding Round Led by Daotong Investment to Advance Innovative Collagen-Based Regenerative Membranes

Recently, Bochuang Biotech completed its angel round of financing, which was exclusively invested by DaoTong Investment's angel fund. It is reported that,The funds from this round of financing will be mainly used for the extraction of high-purity active collagen, the in-depth development of oral bone tissue-guided membrane glue and artificial corneas, as well as the construction of an amplification platform.

Bochuang Biotech was founded in June 2022 and is a leading enterprise in Suzhou Industrial Park. The company has deep collaborations with well-known universities and research institutions such as East China University of Science and Technology and Shanghai University, with its core technology mainly originating from the team led by Academician Changsheng Liu. Leveraging the technical and talent advantages of its founding team, Bochuang Biotech will develop a series of high-end innovative products, including artificial corneas, periosteum, dura mater, and nerve conduits, based on the internationally pioneering "Electrochemical Deposition of Biomacromolecules" (EDP) technology platform. The company is committed to promoting the upgrading of collagen repair products and membrane repair products in China.

Founder of Bochuang Biotech, Professor Xue Qu from East China University of Science and TechnologyStated: "EDP technology, by modulating electrostatic fields to drive the controlled assembly of molecules on electrode surfaces, enables multi-scale biomimetic precision structural control and high-performance tuning of biological tissue functional membranes. This allows the biological tissue functional thin films we prepare to achieve precise structural control at the nano, micro, and macro scales while imparting the desired high performance."

Dr. Tan Haoqi, General Manager of Bochuang BiotechBochuang Biotech stated: "Targeting the two rapidly growing markets of alveolar bone repair and diseased cornea repair in China, Bochuang Biotech will utilize EDP technology to regulate the assembly process of molecules on specially shaped electrode surfaces. The first-phase development will focus on two products: an asymmetric-structure guided bone regeneration membrane for oral use (E-Gide) and a highly transparent, customizable bionic artificial cornea (E-Col). Early research results have shown that the guided bone regeneration membrane (E-Gide) can accelerate the growth of osteogenesis-related cells while limiting the ingrowth of fibroblasts, improving bone augmentation outcomes for patients. The collagen-based artificial cornea (E-Col) can reduce the host's immune rejection response, prevent the ingrowth of new blood vessels and material opacification, maintain high transparency during its service life, and enhance the success rate of corneal repair. Compared with currently available products on the market, these products demonstrate significant advantages in fine structure control, bioactivity, and production costs."

Zhencheng Lin, Managing Director of Daotong InvestmentStated: "We are optimistic about the tremendous potential for the development of the biomaterials industry based on innovative technologies over the long term. Bochuang Biotech, leveraging over a decade of professional expertise from Academician Changsheng Liu’s team in the internationally pioneering fields of biomacromolecules and controlled electrochemical assembly deposition, is commercializing and productizing to develop a series of bio-tissue functional membrane products. The company's innovative products in oral membranes and artificial corneas have already been preliminarily validated. Additionally, the founding team has a track record of successful commercial market experiences, utilizing the fine structural control, bioactivity, and cost advantages of their proprietary products to drive the advancement of the membrane-based biomaterials industry."

Daotong Investment Focuses on Early-Stage Investments in the Healthcare Industry, Prioritizing Innovative Medical Technologies, and Has Been an Early Investor in Multiple Pioneering Domestic Technology Projects. The Daotong Core Team Comes from the Healthcare Industry, Having Successfully Incubated Early-Stage Startups and Established and Managed Listed Companies with a Market Value of Over 10 Billion. Daotong Is Committed to Not Only Being a Value Discoverer But Also a Value Creator, Supporting and Accompanying Enterprise Growth Through In-Depth Post-Investment Empowerment. It Has Repeatedly Earned Honors Such as VC TOP100 and Medical Device TOP20 in the ChinaVenture Awards.